VEGGF - Neonmind signs psilocybin supply agreement with Psygen Labs for clinical trials

NeonMind Biosciences, a majority owned subsidiary of Better Plant Sciences (VEGGF) has inked an agreement with Psygen Labs for the supply of psilocybin for NeonMind's planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety.As Psygen has a pending application for a Dealer's Licence,it is currently acting as broker between NeonMind and a licensed dealer of restricted drugs. "Psilocybin is known to activate serotonin receptors," says Dr. William Panenka, lead scientific advisor to NeonMind. "As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings." According to the World Health Organization,

For further details see:

Neonmind signs psilocybin supply agreement with Psygen Labs for clinical trials